SurgiLight Presents the Clinical Results at the World Refractive Surgery Symposium for its New Laser for Presbyopia.Business Editors/High-Tech & Medical Writers ORLANDO, Fla.--(BUSINESS WIRE)--July 24, 2000 SurgiLight Inc., (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :SRGL SRGL Statement of Recognised Gains and Losses (UK) ) announced today that it presented a paper and demonstrated its new IR-laser system for the treatment of presbyopia Presbyopia Definition The term presbyopia means "old eye" and is a vision condition involving the loss of the eye's ability to focus on close objects. at the World Refractive Surgery Symposium. The Company believes that it is the first company to present the clinical results for the new procedures of presbyopia reversal using an infrared (IR) laser. The Company's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , J. T. Lin, Ph.D, presented a paper at the Summer Refractive Surgery Symposium held in Miami, FL (July 21-23), where the co-authors of this paper are A. Perraso, MD and D. Martiniz, (SurgiLight's Microsurgery microsurgery or micromanipulation Surgical technique for operating on minute structures, with specialized, tiny precision instruments under observation through a microscope, sometimes equipped with cameras to show the operation on a monitor. Center in Venezuela). Clinical results on 35 cases of presbyopic patients, age ranging from 42 to 65 and follow-up between few weeks to over 13 months was reported. These clinical results show that 86% of the treated patient can read J3 or better after the surgery and most of the patients were treated both eyes with very high patient satisfaction. In addition, almost no regression was found up to 13 months post operation follow-up. The Company believes that its new IR-laser has great advantages over the existing non-laser methods and maybe a more effective tool for the correction of presbyopia which is estimated to have a potential market over $150 billion in US alone. At the World Refractive Surgery Symposium, the Company exhibited its IR-3000 system which the Company believes is the first working system in the world for the new procedure called Laser Presbyopia Reversal (LAPR LAPR Lawfully Admitted for Permanent Residency LAPR Log A Posteriori Ratio LAPR LaMar Ayers Public Relations Group (Washington, DC) ). This new procedure of LAPR, the Company believes, can not be achieved by any other existing technologies including the Excimer lasers made by Visx (Nasdaq:VISX), Summit Nasdaq:BEAM), LaserSight (Nasdaq:LASE), Nidek (Japan) and Bausch & Lomb (NYSE NYSE See: New York Stock Exchange :BOL), or the thermal laser made by Sunrise International (Nasdaq: SNRS SNRS Securing Networks with Cisco Routers and Switches SNRS Southern Nursing Research Society ). To protect the new IR-laser technologies, the Company currently has four US pending patents, which cover a broad range of laser spectra, and many innovative devices regarding the new procedure of LAPR. The Company plans to start additional clinical trial sites in Japan, Europe and US shortly. SurgiLight is a world leader in the development of new infrared technologies, a pioneer and inventor of scanning lasers and lasers for presbyopia reversal. The Company continues to receive royalty income from international eye laser and cosmetic centers. This press release may contain forward-looking statements regarding future events and performance of the Company, which involves risks and uncertainties that could materially affect actual results. Investors should refer to documents that the Company files with the SEC for a description of certain factors that could cause actual results to vary from current expectations and the forward-looking statements contained in this press release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion